ABVC completes partial spinoff of BioKey (Cayman) subsidiary
ABVC BioPharma distributed roughly 15% of BioKey Cayman shares to its stockholders on August 21, 2026, while keeping majority control.
SEC filing
Latest
2 stories
Thursday, August 27
Monday, August 17
ABVC BioPharma flags going-concern doubt in 10-Q, delays BioKey Cayman spinoff
The company's June 30, 2026 quarterly report cites a $2.5 million six-month net loss and a working capital deficit, while a planned partial spinoff of subsidiary BioKey Cayman has been pushed back.
SEC filing (4)